Feeds:
Posts
Comments

terrific in every respect

Biochemical Insights of Dr. Jose Eduardo de Salles Roselino

Larry H. Bernstein, MD, FCAP, Interviewer, Curator

Leaders in Pharmaceutical Intelligence

Biochemical Insights of Dr. Jose Eduardo de Salles Roselino

http://pharmaceuticalintelligence.com/12/24/2014/larryhbern/Biochemical_
Insights_of_Dr._Jose_Eduardo_de_Salles_Roselino/

Article ID #165: Biochemical Insights of Dr. Jose Eduardo de Salles Roselino. Published on 12/17/2014

WordCloud Image Produced by Adam Tubman

Biochemical Insights of Dr. Jose Eduardo de Salles Roselino

How is it that developments late in the 20th century diverted the attention of
biological processes from a dynamic construct involving interacting chemical
reactions under rapidly changing external conditions effecting tissues and cell
function to a rigid construct that is determined unilaterally by the genome
construct, diverting attention from mechanisms essential for seeing the complete
cellular construct?

Larry, I assume that in case you read the article titled Neo – Darwinism, The
Modern Synthesis and Selfish Genes that bares no relationship with Physiology
with Molecular Biology J. Physiol 2011; 589(5): 1007-11 by Denis Noble, you might
find that it was the key factor required in order to understand the dislodgment
of physiology as a foundation of medical reasoning. In the near unilateral emphasis
of genomic activity as a determinant of cellular activity all of the required general
support for the understanding of my reasoning. The DNA to protein link goes
from triplet sequence to amino acid sequence. That is the realm of genetics.
Further, protein conformation, activity and function requires that environmental
and micro-environmental factors should be considered (Biochemistry). If that
were not the case, we have no way to bridge the gap between the genetic
code and the evolution of cells, tissues, organs, and organisms.

  • Consider this example of hormonal function. I would like to stress in
    the cAMP dependent hormonal response, the transfer of information
    that 
    occurs through conformation changes after protein interactions.
    This mechanism therefore, requires that proteins must not have their
    conformation determined by sequence alone.
    Regulatory protein conformation is determined by its sequence plus
    the interaction it has in its micro-environment. For instance, if your
    scheme takes into account what happens inside the membrane and
    that occurs before cAMP, then production is increased by hormone
    action. A dynamic scheme  will show an effect initially, over hormone
    receptor (hormone binding causing change in its conformation) followed
    by GTPase change in conformation caused by receptor interaction and
    finally, Adenylate cyclase change in conformation and in activity after
    GTPase protein binding in a complex system that is dependent on self-
    assembly and also, on changes in their conformation in response to
    hormonal signals (see R. A Kahn and A. G Gilman 1984 J. Biol. Chem.
    v. 259,n 10 pp6235-6240. In this case, trimeric or dimeric G does not
    matter). Furthermore, after the step of cAMP increased production we
    also can see changes in protein conformation.  The effect of increased
    cAMP levels over (inhibitor protein and protein kinase protein complex)
    also is an effect upon protein conformation. Increased cAMP levels led
    to the separation of inhibitor protein (R ) from cAMP dependent protein
    kinase (C ) causing removal of the inhibitor R and the increase in C activity.
    R stands for regulatory subunit and C for catalytic subunit of the protein
    complex.
  • This cAMP effect over the quaternary structure of the enzyme complex
    (C protein kinase + R the inhibitor) may be better understood as an
    environmental information producing an effect in opposition to
    what may be considered as a tendency  towards a conformation
    “determined” by the genetic code. This “ideal” conformation
    “determined” by the genome  would be only seen in crystalline
    protein.
     In carbohydrate metabolism in the liver the hormonal signal
    causes a biochemical regulatory response that preserves homeostatic
    levels of glucose (one function) and in the muscle, it is a biochemical
    regulatory response that preserves intracellular levels of ATP (another
    function).
  • Therefore, sequence alone does not explain conformation, activity
    and function of regulatory proteins
    .  If this important regulatory
    mechanism was  not ignored, the work of  S. Prusiner (Prion diseases
    and the BSE crisis Stanley B. Prusiner 1997 Science; 278: 245 – 251,
    10  October) would be easily understood.  We would be accustomed
    to reason about changes in protein conformation caused by protein
    interaction with other proteins, lipids, small molecules and even ions.
  • In case this wrong biochemical reasoning is used in microorganisms.
    Still it is wrong but, it will cause a minor error most of the time, since
    we may reduce almost all activity of microorganism´s proteins to a
    single function – The production of another microorganism. However,
    even microorganisms respond differently to their micro-environment
    despite a single genome (See M. Rouxii dimorphic fungus works,
    later). The reason for the reasoning error is, proteins are proteins
    and DNA are DNA quite different in chemical terms. Proteins must
    change their conformation to allow for fast regulatory responses and
    DNA must preserve its sequence to allow for genetic inheritance.

Updated on 2/18/2020 1,539 Total Views of Presentations @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

Reporter: Aviva Lev-Ari, PhD, RN

 

Real Time Media Conference Coverage  –  Business and Scientific Channels:

Aviva Lev-Ari, PhD, RN @ https://pharmaceuticalintelligence.com 

Views Data Summaries on WordPress.com

Data Compilation: Aviva Lev-Ari, PhD, RN

UPDATED on 2/18/2020

Total Views per entry:

  • 13 Lectures Sessions: 561 Views
  • Five related articles: 211 Views
  • Announcement for the Event: 767 Views
  • Total View of 2/28/2020: 1,539 Views
14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment, 30th September – 1st October 2014 • Congress Center Basel, SACHS Associates, London PLUS 13 Lectures PLUS 5 related articles
767
Total of views for the Announcement = 767 PLUS for 13 Lectures Sessions = 561 views as articles PLUS the other 5 Summary Articles = 211 Views as stand alone Articles related to this event [Total event related VIEWs =1539 – 211 views (Summaries) – 561 views (13 Lectures Sessions)= 767 views for e-Proceedings and 91 views for Collection of Tweets] Add $100 x 48
http://www.sachsforum.com/zurich14/index.html
https://pharmaceuticalintelligence.com/2014/03/25/14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associates-london/
Content of the Presentations at 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London. THIS IS the e-Proceedings with Links to all 13 Lectures Sessions. There are 561 Views on 13 Lectures Sessions of the event
48
Tweeting on 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London
91
https://pharmaceuticalintelligence.com/2014/10/06/content-of-the-presentations-at-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associates-london/
https://pharmaceuticalintelligence.com/2014/10/06/tweeting-on-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associates-london/
Statistics of the Strategy for Event Joint Promotion – Total of 415 Views
29
Statistical Analysis of Tweet Feeds – Four Twitters Accounts in Tandem – @14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London
35
https://pharmaceuticalintelligence.com/2014/10/12/strategy-for-event-joint-promotion-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associates-london/
https://pharmaceuticalintelligence.com/2014/10/12/statistical-analysis-of-tweet-feeds-from-the-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associa/
1,058 Total Views of Presentations @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London
8
https://pharmaceuticalintelligence.com/2014/12/15/1058-total-views-of-presentations-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/

 

# Views on 12.15.2014

Presentation title

URL

 

467 VIEWS

      14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment

30th September – 1st October 2014 • Congress Center Basel

http://pharmaceuticalintelligence.com/2014/03/25/14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associates-london/ 

27

8:30AM – 9/30/2014: Future of Specialty Pharma in Europe @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/09/30/830am-9302014-future-of-specialty-pharma-in-europe-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/

30

9:30AM – Keynote Speech by Anthony Rosenberg, Head of Business Development and Licensing, Novartis Pharma AG – “Global M&A: a Novartis Perspective”

http://pharmaceuticalintelligence.com/2014/09/30/915am-9302014-public-markets-and-ma-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/ 

12

10:45AM – 9/30/2014: Keynote Speech by Reinhard Ambros, Global Head, Novartis Venture Fund @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/09/30/1045am-9302014-keynote-speech-by-reinhard-ambros-global-head-novartis-venture-fund-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/ 

24

12:00AM – 9/30/2014: Oncology I – Building the Cancer Focused Biotech @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/09/30/1200am-9302014-oncology-i-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/ 

113

2:00PM – 9/30/2014: Oncology II – Next Gen Immunotherapeutics @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

 

http://pharmaceuticalintelligence.com/2014/09/30/200pm-9302014-oncology-ii-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/ 

37

BLOOMBERG NEWS INTERVIEWS

Dr. Sophie Kornowaski-Bonnet, Head of Roche Partnering Interviewed by Bloomberg News

 

http://pharmaceuticalintelligence.com/2014/09/30/dr-sophie-kornowaki-bonnet-head-of-roche-partnering-interviewed-by-bloomberg-news/ 

30

BLOOMBERG NEWS INTERVIEWS

Iris Welten, CEO Basel Area, Interview with Bloomberg News at Sachs Associates in Basel

http://pharmaceuticalintelligence.com/2014/09/30/iris-welten-ceo-basel-area-interview-with-bloomberg-news-at-sachs-associates-in-basel/

 50

4:00PM – 9/30/2014: Platform Technologies & Novel Therapeutics @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/09/30/400pm-9302014-platform-technologies-novel-therapeutics-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/

27

17:00PM – 9/30/2014: Company Presentations @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/09/30/1700pm-9302014-company-presentations-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/

20

9:00AM – 10/1/2014: Partnering I @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/10/01/90am-1012014-partnering-i-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/ 

8

10:00AM – 10/1/2014: Partnering II @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/10/01/1000am-1012014-partnering-ii-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/ 

28

11:00AM – 10/1/2014: Scientific Collaborations  @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/10/01/1100am-1012014-scientific-collaborations-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/ 

26

12:30AM – 10/1/2014: Company Presentations @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates,http://pharmaceuticalintelligence.com/2014/10/01/1230-1012014-company-presentations-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/

9

14:00PM – 10/1/2014: Conference Workshop “Conundrums and Conflicts in Licensing & M&A Deals” @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/10/01/1400pm-1012014-conference-workshop-conundrums-and-conflicts-in-licensing-ma-deals-14th-global-partnering-biotech-investment-congress-center-basel/

 19

2:45PM – 9/30/2014: Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences Biotech in Israel @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/09/30/245pm-9302014-biotech-in-israel-14th-global-partnering-biotech-investment-congress-center-basel-sachs-associates-london/

39

Content of the Presentations at 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS

http://pharmaceuticalintelligence.com/2014/10/06/content-of-the-presentations-at-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associates-london/

61

Tweeting on 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, London

http://pharmaceuticalintelligence.com/2014/10/06/tweeting-on-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associates-london/

31

Statistical Analysis of Tweet Feeds from the 14th ANNUAL BIOTECH IN EUROPE FORUM For Global Partnering & Investment 9/30 – 10/1/2014 • Congress Center Basel – SACHS Associates, Londonhttp://pharmaceuticalintelligence.com/2014/10/12/statistical-analysis-of-tweet-feeds-from-the-14th-annual-biotech-in-europe-forum-for-global-partnering-investment-930-1012014-•-congress-center-basel-sachs-associa/

 

TOTAL Views: 1,058

x

Reprogramming Normal Cell Lines into Stem-like Cells

Reporter: Aviva Lev-Ari, PhD, RN

 

 

More information: “Actin stress in cell reprogramming.” PNAS 2014 111 (49) E5252-E5261; published ahead of print November 24, 2014, DOI: 10.1073/pnas.1411683111

Read more at: http://phys.org/news/2014-12-mechanical-cues-reprogram-cell-lines.html#jCp

and

http://phys.org/news/2014-12-mechanical-cues-reprogram-cell-lines.html

Mechanical cues reprogram normal cell lines into stem-like cells

Dec 11, 2014 by Ellen Goldbaum

Scientists at the University at Buffalo and other institutions have turned cells normally used as model cells, known as immortalized cells, into stem or, as they call it, “stem-like” cells, using nothing more than mechanical stress. They have done it without employing the potentially hazardous techniques previously used to obtain similar results.

mechanicalcu

 

The finding is described in a paper published recently online before print in the Proceedings of the National Academy of Sciences. The researchers discovered that by changing the mechanical stresses on neuronal and other cell types in tissue culture allowed them to be reprogrammed into “stem-like” cells.

“Normal cell types in  are spread out and have differentiated internal structures, but changing cell mechanics caused the cells to turn into clusters of spherical cells that had many of the biochemical markers of cells,” says Frederick Sachs, PhD, SUNY Distinguished Professor in the UB Department of Physiology and Biophysics and senior author.

Read more at: http://phys.org/news/2014-12-mechanical-cues-reprogram-cell-lines.html#jCp

 

Biologically Distinct Breast Cancer Subtypes: The Role of Epigenetics

Reporter: Aviva Lev-Ari, PhD, RN

 

 

Article reference

A DNA methylation-based definition of biologically distinct breast cancer subtypes. Stefansson OA, Moran S, Gomez A, Sayols S, Arribas-Jorba C, Sandoval J, Hilmarsdottir H, Ólafsdóttir I, Tryggvadottir L, Jonasson JG, Eyfjord J, Esteller M. Molecular Oncology, PII: S1574-7891 (14) 00261 -0, 2014.

Mol Oncol. 2014 Nov 5. pii: S1574-7891(14)00261-0. doi: 10.1016/j.molonc.2014.10.012. [Epub ahead of print]

A DNA methylation-based definition of biologically distinct breast cancer subtypes.

Abstract

In cancer, epigenetic states are deregulated and thought to be of significance in cancer development and progression. We explored DNA methylation-based signatures in association with breast cancer subtypes to assess their impact on clinical presentation and patient prognosis. DNA methylation was analyzed using Infinium 450K arrays in 40 tumors and 17 normal breast samples, together with DNA copy number changes and subtype-specific markers by tissue microarrays. The identified methylation signatures were validated against a cohort of 212 tumors annotated for breast cancer subtypes by the PAM50 method (The Cancer Genome Atlas). Selected markers were pyrosequenced in an independent validation cohort of 310 tumors and analyzed with respect to survival, clinical stage and grade. The results demonstrate that DNA methylation patterns linked to the luminal-B subtype are characterized by CpG island promoter methylation events. In contrast, a large fraction of basal-like tumors are characterized by hypomethylation events occurring within the gene body. Based on these hallmark signatures, we defined two DNA methylation-based subtypes, Epi-LumB and Epi-Basal, and show that they are associated with unfavorable clinical parameters and reduced survival. Our data show that distinct mechanisms leading to changes in CpG methylation states are operative in different breast cancer subtypes. Importantly, we show that a few selected proxy markers can be used to detect the distinct DNA methylation-based subtypes thereby providing valuable information on disease prognosis.

NEW BREAST CANCER CLASSIFICATION BASED ON EPIGENETICS.

PowerPoint Presentation

Researchers from Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) have established the epigenetic patterns of breast cancer and also its clinical consequences. The opensource study is published in the journal Molecular Oncology.

Statistics from The Breast Cancer Research Foundation state that nearly 1.7 million new breast cancer cases were diagnosed in 2012.  Breast cancer is the second most common cancer in women and men worldwide. In 2012, it represented about 12 percent of all new cancer cases and 25 percent of all cancers in women.  Breast cancer is the most frequently diagnosed cancer among women in 140 of 184 countries worldwide.

Globally, breast cancer now represents one in four of all cancers in women.  Progress in prevention and early detection, and the use of chemotherapy after surgery (adjuvant chemotherapy), have achieved significantly increase survival in this disease in the last ten years, but much remains to be done.

The identification of patients with high-risk breast cancer is key to knowing whether a patient will require only the removal of the tumour by surgery or whether if they will need additional chemotherapy to make sure the removal of breast cancer cells. Currently, known genetic mutations and expression patterns are determined, but the puzzle of the genetics of the disease remains a large unfinished part.

To address this the researchers analyzed epigenetic alterations, namely the chemical signal called DNA methylation in 500 breast tumours and have compared the patterns obtained with the clinical behaviour of these cancers.

The team note that there are two subgroups of breast tumours by epigenome; one which they have named Epi-Basal, characterized by loss of epigenetic marks causing breakage of chromosomes and the other that the researchers have called Epi-Luminal B, that presents epigenetic inactivation of genes that should protect humans from cancer and the altered cells that can no longer do it.

The researchers highlight that the subtype Epi-Luminal B behaves particularly aggressive form, and is associated with reduced survival of patients. They would therefore recommend that with this class of tumour the medical team avoid surgery and instead administer adjuvant chemotherapy and in those tumours with a more ‘benign’ epigenetic pattern; surgery alone may be curative, thus avoiding the side effects of chemotherapy.

Source:  Institut d’Investigació Biomèdica de Bellvitge

DNA methylation changes in breast tumors are non-random and define patterns correlated with clinically and biologically relevant subtypes. A) Cluster analysis of differentially methylated CpGs between breast cancers and normal breast tissue (the top 5000 most significant CpGs). Tumor characteristics (by columns on top of the heat-map) in terms of breast cancer subtype along with the presence of acquired mutations in the TP53 gene are displayed together with the CpG context (by rows on the left-hand side) according to the color scheme shown at the right-hand side and bottom of the figure, respectively. The statistically significant tumor patterns/clusters (identified by the pvclust method in R) are shown as colored bars immediately below the dendrogram. B) The top 10 significant CpG's specifically characterizing each of the four “core” subtypes are shown, i.e. the LumA, LumB, HER2 and Basal-like subtypes. Note, 5NP (i.e. unclassified tumors due to negativity for all five phenotypic markers, i.e. ER, PR, HER2, CK5/6 and EGFR) and breast tumors with unknown subtype information are grouped together as 5NP/NA and were not included in this analysis. The normal breast tissue samples are shown and indicated in black on top of the heat-map. Note, the heat-map colors reflect beta-values representing the degree of methylation from low to high as green to red, respectively (wherein black represents heterogenous/hemi-methylation), as shown on the scale at the top-right hand side of the figure.  A DNA methylation-based definition of biologically distinct breast cancer subtypes.  Esteller et al 2014.

 

Dynamic myocardial CT perfusion imaging for evaluation of myocardial ischemia as determined by MR imaging | DSCT.com – Your Dual-source CT experts

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

The aim of this study was to determine the feasibility of CT-based dynamic myocardial perfusion imaging for the assessment of myocardial ischemia and infarction compared with cardiac magnetic resonance (CMR).

Source: www.dsct.com

See on Scoop.itCardiovascular and vascular imaging

Impairment of vascularization of the surface covering epithelium induces ischemia and promotes malignization: a new hypothesis of a possible mechanism of cancer pathogenesis – Online First – Springer

Reporter: Aviva Lev-Ari, PhD, RN

Impairment of vascularization of the surface covering epithelium induces ischemia and promotes malignization: … http://t.co/752c9CuBzz

Source: link.springer.com

See on Scoop.itCardiovascular and vascular imaging

“@smithECGBlog: A Hybrid of de Winter’s T-waves and Diffuse Subendocardial Ischemia: #FOAMed http://t.co/IBTUwRX5KE http://t.co/LSFDBp1ipa”

Source: hqmeded-ecg.blogspot.fr

See on Scoop.itCardiovascular and vascular imaging

Myocardial ischemia common in young women with CHD under mental stress | Cardiology

Reporter: Aviva Lev-Ari, PhD, RN

 

 

 

Cardiology | CHICAGO — Women aged 55 years and younger with stable CHD under mental stress are more likely to develop myocardial ischemia than men of the same age.

Source: www.healio.com

See on Scoop.itCardiovascular and vascular imaging